Wells Fargo & Company MN increased its stake in shares of Crispr Therapeutics AG (NASDAQ:CRSP) by 129.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,352 shares of the company’s stock after acquiring an additional 10,365 shares during the period. Wells Fargo & Company MN’s holdings in Crispr Therapeutics were worth $328,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently bought and sold shares of the stock. Capital Investment Advisory Services LLC acquired a new stake in Crispr Therapeutics in the third quarter valued at approximately $193,000. Ark Investment Management LLC acquired a new stake in Crispr Therapeutics in the second quarter valued at approximately $206,000. Moloney Securities Asset Management LLC acquired a new stake in Crispr Therapeutics in the third quarter valued at approximately $235,000. Vanguard Group Inc. acquired a new stake in Crispr Therapeutics in the second quarter valued at approximately $273,000. Finally, Bank of New York Mellon Corp acquired a new stake in Crispr Therapeutics in the third quarter valued at approximately $288,000. 22.74% of the stock is currently owned by hedge funds and other institutional investors.
CRSP has been the topic of several research reports. Cann restated a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. SunTrust Banks restated a “hold” rating and issued a $16.00 target price on shares of Crispr Therapeutics in a research report on Friday, November 10th. BidaskClub downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Oppenheimer initiated coverage on Crispr Therapeutics in a research report on Thursday, December 7th. They issued a “hold” rating on the stock. Finally, Piper Jaffray Companies initiated coverage on Crispr Therapeutics in a research report on Friday, December 22nd. They set an “overweight” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $22.81.
Crispr Therapeutics AG (CRSP) traded down $3.76 during mid-day trading on Monday, reaching $34.88. The company’s stock had a trading volume of 2,072,500 shares, compared to its average volume of 1,097,445. The firm has a market capitalization of $1,600.68, a PE ratio of -27.41 and a beta of 9.84. Crispr Therapeutics AG has a one year low of $11.63 and a one year high of $45.00.
In related news, major shareholder Corp /De/ Celgene sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $17.67, for a total transaction of $265,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Aktiengesellschaft Bayer bought 527,472 shares of the stock in a transaction that occurred on Friday, January 5th. The shares were bought at an average cost of $22.75 per share, with a total value of $11,999,988.00. The disclosure for this purchase can be found here. In the last three months, insiders have sold 2,040,450 shares of company stock valued at $40,821,755. 39.98% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This news story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://stocknewstimes.com/2018/02/12/wells-fargo-company-mn-raises-stake-in-crispr-therapeutics-ag-crsp.html.
Crispr Therapeutics Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Crispr Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.